Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 73 AEP72 | DOI: 10.1530/endoabs.73.AEP72

Hedi Chaker Hospital, Endocrinology, Sfax, Tunisia


Introduction

Recent studies in patients with Addison’s disease have shown that this condition, even if treated, is fraught with significant morbidity and even excess mortality. The objective of our study was to determine the deleterious effects of long-term glucocorticoid replacement mainly on the metabolic level.

Methods

Retrospective study, carried out at the Endocrinology and Diabetology Department of Hédi Chaker Sfax University Hospital, which involved 32 patients with Addison’s disease that has been evolving for more than 15 years.

Results

The average age was 58.53 years with a predominance of women. The mean duration of follow-up was 17.87 years. The hydrocortisone dose was initially 32.5 mg/d, at the end of 27.9 mg/d. There was gradual weight gain, an increase in body mass index and waist circumference. The prevalence of MS was 3.12% at diagnosis and 35.71% after treatment duration greater than 15 years. At the end of the follow-up, 28.57% of the obese patients against 7.14% at the discovery of the disease were noted, 25% of the hypertensive and type 2 diabetic patients all appeared throughout the follow-up, 42.85% of the dyslipidemic patients. Factors favoring the occurrence of the metabolic syndrome were the duration of the disease and the weight loss on discovery of the disease.

Conclusion

Adjustment of replacement therapy during Addison’s disease is an issue in view of the morbidity and mortality associated with overdose. Regular monitoring and a personalized therapeutic approach are necessary to improve the prognosis of his patients.

Volume 73

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.